Cargando…

Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo Survival

Our rationale was to build a refined dosimetry model for (177)Lu-DOTATATE in vivo experiments enabling the correlation of absorbed dose with double-strand break (DSB) induction and cell death. Methods: Somatostatin receptor type 2 expression of NCI-H69 xenografted mice, injected with (177)Lu-DOTATAT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamborino, Giulia, Nonnekens, Julie, De Saint-Hubert, Marijke, Struelens, Lara, Feijtel, Danny, de Jong, Marion, Konijnenberg, Mark W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2022
Materias:	Basic (Radiobiology/Dosimetry/Safety)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717202/ https://www.ncbi.nlm.nih.gov/pubmed/33837068 http://dx.doi.org/10.2967/jnumed.121.262122

Ejemplares similares

Targeting Micrometastases: The Effect of Heterogeneous Radionuclide Distribution on Tumor Control Probability
por: Falzone, Nadia, et al.
Publicado: (2019)

PET-Based Human Dosimetry of (68)Ga-NODAGA-Exendin-4, a Tracer for β-Cell Imaging
por: Boss, Marti, et al.
Publicado: (2020)

γ-Tocotrienol–Loaded Liposomes for Radioprotection from Hematopoietic Side Effects Caused by Radiotherapeutic Drugs
por: Lee, Sang-gyu, et al.
Publicado: (2021)

Dosimetric Considerations in Radioimmunotherapy and Systemic Radionuclide Therapies: A Review
por: Loke, Kelvin S. H., et al.
Publicado: (2011)

Modeling Early Radiation DNA Damage Occurring During (177)Lu-DOTATATE Radionuclide Therapy
por: Tamborino, Giulia, et al.
Publicado: (2022)

Short fractionation radiotherapy for early prostate cancer in the time of COVID-19: long-term excellent outcomes from a multicenter Italian trial suggest a larger adoption in clinical practice
por: Barra, Salvina, et al.
Publicado: (2020)

Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward
por: Feijtel, Danny, et al.
Publicado: (2020)

Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response
por: Feijtel, Danny, et al.
Publicado: (2021)

Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
por: Tamborino, Giulia, et al.
Publicado: (2020)

Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy
por: Mora‐Ramirez, Erick, et al.
Publicado: (2020)

The Biological Basis for Enhanced Effects of Proton Radiation Therapy Relative to Photon Radiation Therapy for Head and Neck Squamous Cell Carcinoma
por: Wang, Li, et al.
Publicado: (2021)

In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib
por: Feijtel, Danny, et al.
Publicado: (2023)

Regulation of O(2) consumption by the PI3K and mTOR pathways contributes to tumor hypoxia
por: Kelly, Catherine J., et al.
Publicado: (2014)

Influence of chronic hypoxia and radiation quality on cell survival
por: Ma, Ning-Yi, et al.
Publicado: (2013)

Initial clinical experience with scanned proton beams at the Italian National Center for Hadrontherapy (CNAO)
por: Tuan, J., et al.
Publicado: (2013)

Hadron therapy information sharing prototype
por: Roman, Faustin Laurentiu, et al.
Publicado: (2013)

Data-driven Markov models and their application in the evaluation of adverse events in radiotherapy
por: Abler, Daniel, et al.
Publicado: (2013)

Quality of life in patients with chordomas/chondrosarcomas during treatment with proton beam therapy
por: Srivastava, A., et al.
Publicado: (2013)

Influence of acute hypoxia and radiation quality on cell survival
por: Tinganelli, Walter, et al.
Publicado: (2013)

Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression()
por: Groselj, Blaz, et al.
Publicado: (2013)

A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT)
por: Spoormans, Kaat, et al.
Publicado: (2022)

Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Patient‐derived heterogeneous breast phantoms for advanced dosimetry in mammography and tomosynthesis
por: Caballo, Marco, et al.
Publicado: (2022)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

In Vitro comparison of (213)Bi- and (177)Lu-radiation for peptide receptor radionuclide therapy
por: Chan, Ho Sze, et al.
Publicado: (2017)

In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies
por: Chatalic, Kristell L.S., et al.
Publicado: (2016)

Training in intraoperative handover and display of a checklist improve communication during transfer of care: An interventional cohort study of anaesthesia residents and nurse anaesthetists
por: Jullia, Marion, et al.
Publicado: (2017)

Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments
por: Bison, Sander M., et al.
Publicado: (2014)

A Clinical Guide to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients
por: Becx, Morticia N., et al.
Publicado: (2022)

Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study
por: Rechner, Laura Ann, et al.
Publicado: (2020)

Preclinical dosimetry in proton minibeam radiation therapy: Robustness analysis and guidelines
por: Ortiz, Ramon, et al.
Publicado: (2022)

Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases
por: Falzone, Nadia, et al.
Publicado: (2018)

Dosimetric Analysis of the Short-Ranged Particle Emitter (161)Tb for Radionuclide Therapy of Metastatic Prostate Cancer
por: Bernhardt, Peter, et al.
Publicado: (2021)

The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
por: Ruigrok, Eline A.M., et al.
Publicado: (2019)

Development and evaluation of a GEANT4‐based Monte Carlo Model of a 0.35 T MR‐guided radiation therapy (MRgRT) linear accelerator
por: Khan, Ahtesham Ullah, et al.
Publicado: (2021)

A feasibility study of the therapeutic application of a mixture of (67/64)Cu radioisotopes produced by cyclotrons with proton irradiation
por: De Nardo, Laura, et al.
Publicado: (2022)

DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo
por: Reuvers, Thom G.A., et al.
Publicado: (2023)

Fast technetium‐99m liver SPECT for evaluation of the pretreatment procedure for radioembolization dosimetry
por: van der Velden, Sandra, et al.
Publicado: (2018)

Technical Note: Characterization of the new microSilicon diode detector
por: Schönfeld, Ann‐Britt, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kfbmskpccpfo0jsas4otc7iqg7